AU2021299197A1 - Modified release formulations of modified forms of trimetazidine - Google Patents

Modified release formulations of modified forms of trimetazidine Download PDF

Info

Publication number
AU2021299197A1
AU2021299197A1 AU2021299197A AU2021299197A AU2021299197A1 AU 2021299197 A1 AU2021299197 A1 AU 2021299197A1 AU 2021299197 A AU2021299197 A AU 2021299197A AU 2021299197 A AU2021299197 A AU 2021299197A AU 2021299197 A1 AU2021299197 A1 AU 2021299197A1
Authority
AU
Australia
Prior art keywords
imb
hours
trimetazidine
dose
hpmc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021299197A
Other languages
English (en)
Inventor
Scott Herbig
Andrew D. LEVIN
George MOONEY
Jaikrishna Patel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Imbria Pharmaceuticals Inc
Original Assignee
Imbria Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Imbria Pharmaceuticals Inc filed Critical Imbria Pharmaceuticals Inc
Publication of AU2021299197A1 publication Critical patent/AU2021299197A1/en
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1652—Polysaccharides, e.g. alginate, cellulose derivatives; Cyclodextrin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
AU2021299197A 2020-06-30 2021-06-28 Modified release formulations of modified forms of trimetazidine Pending AU2021299197A1 (en)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US202063046117P 2020-06-30 2020-06-30
US202063046115P 2020-06-30 2020-06-30
US63/046,117 2020-06-30
US63/046,115 2020-06-30
US202163183299P 2021-05-03 2021-05-03
US202163183294P 2021-05-03 2021-05-03
US63/183,299 2021-05-03
US63/183,294 2021-05-03
PCT/US2021/039303 WO2022005926A1 (en) 2020-06-30 2021-06-28 Modified release formulations of modified forms of trimetazidine

Publications (1)

Publication Number Publication Date
AU2021299197A1 true AU2021299197A1 (en) 2023-02-02

Family

ID=79315460

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021299197A Pending AU2021299197A1 (en) 2020-06-30 2021-06-28 Modified release formulations of modified forms of trimetazidine

Country Status (8)

Country Link
EP (1) EP4171232A4 (https=)
JP (1) JP2023531802A (https=)
KR (1) KR20230028535A (https=)
CN (1) CN116234555A (https=)
AU (1) AU2021299197A1 (https=)
CA (1) CA3187827A1 (https=)
IL (1) IL299544A (https=)
WO (1) WO2022005926A1 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
KR20250035269A (ko) * 2023-09-05 2025-03-12 주식회사 뉴캔서큐어바이오 트리메타지딘을 포함하는 코팅정 조성물 및 이의 제조방법

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101466371B (zh) * 2006-06-09 2011-10-05 施瓦茨制药有限公司 含非索罗定的稳定的药用组合物
PE20080669A1 (es) * 2006-09-08 2008-07-18 Drugtech Corp Composicion de liberacion sostenida que comprende levodopa
ITFI20130184A1 (it) * 2013-08-01 2015-02-02 Valpharma Internat S P A Una formulazione farmaceutica di gliclazide a rilascio modificato, somministrabile per via orale, e suo metodo di produzione.
NZ745921A (en) * 2016-03-09 2021-12-24 Nls 1 Pharma Ag A mazindol ir/sr multilayer tablet and its use for the treatment of attention deficit/hyperactivity disorder (adhd)
IL283725B2 (en) * 2017-06-20 2024-04-01 Imbria Pharmaceuticals Inc Compositions and methods for increasing efficiency of cardiac metabolism
US10980747B2 (en) * 2017-11-27 2021-04-20 Shin-Etsu Chemical Co., Ltd. Composition for solid preparation, solid preparation, and method for producing the same
CN109908096A (zh) * 2017-12-12 2019-06-21 武汉武药科技有限公司 一种盐酸曲美他嗪缓释片及其制备方法
EP3866794B1 (en) * 2018-10-17 2024-12-04 Imbria Pharmaceuticals, Inc. Methods of treating rheumatic diseases using trimetazidine-based compounds

Also Published As

Publication number Publication date
EP4171232A1 (en) 2023-05-03
IL299544A (en) 2023-02-01
JP2023531802A (ja) 2023-07-25
CA3187827A1 (en) 2022-01-06
WO2022005926A1 (en) 2022-01-06
KR20230028535A (ko) 2023-02-28
CN116234555A (zh) 2023-06-06
EP4171232A4 (en) 2024-07-24

Similar Documents

Publication Publication Date Title
JP4108980B2 (ja) 持続放出ラノラジン製剤
KR101721198B1 (ko) 테트라하이드로바이오프테린 투여 방법, 관련 조성물 및 측정 방법
US20250221986A1 (en) Methods of treating kidney conditions using modified forms of trimetazidine
UA75027C2 (uk) Спосіб лікування серцево-судинних захворювань лікарською формою ранолазину пролонгованої дії
US20250009665A1 (en) Gastro-resistant controlled release oral dosage forms
BRPI0708059A2 (pt) formulação de niacina de baixo rubor
WO2015089150A1 (en) Pharmaceutical formulations comprising vilazodone
US20240277698A1 (en) Methods of using aldosterone synthase inhibitors
TW200810792A (en) Immediate-release tablet formulations of a thrombin receptor antagonist
US20240082242A1 (en) Combination therapies
US20230210845A1 (en) Dosing methods for treatment of cardiovascular conditions
US20210401833A1 (en) Modified release formulations of modified forms of trimetazidine
AU2021299197A1 (en) Modified release formulations of modified forms of trimetazidine
EP4243782B1 (en) Tablet for use in treating huntington's disease and method of making the same
US20210401834A1 (en) Modified release formulations of modified forms of trimetazidine
US20070053975A1 (en) Ramipril formulation
CA3236328A1 (en) Methods of treating cardiovascular conditions and methods of increasing the efficiency of cardiac metabolism
CN117545482A (zh) 使用醛固酮合酶抑制剂的方法
Tablets et al. PrTEVA-DILTIAZEM XC
US20120028976A1 (en) Pharmacokinetically-based dosing regiments of a thrombin receptor antagonist
INC PrM-NIFEDIPINE ER
Laval Antihypertensive/Antianginal Agent
Tablets et al. Pr SANDOZ SAXAGLIPTIN
EA048709B1 (ru) Таблетка для применения в лечении болезни хантингтона и способ ее приготовления
HK40101454A (en) Tablet for use in treating huntington's disease and method of making the same